Organon & Co.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $6.22B | $6.40B | $6.26B | $6.17B | $6.30B | $6.53B | $7.78B |
| Cost of Revenue | $2.90B | $2.69B | $2.52B | $2.29B | $2.38B | $2.12B | $2.27B |
| Gross Profit | $3.31B | $3.72B | $3.75B | $3.88B | $3.92B | $4.41B | $5.50B |
| Gross Margin | 53.3% | 58.0% | 59.8% | 62.8% | 62.2% | 67.6% | 70.8% |
| Operating Expenses | |||||||
| Research & Development | — | — | — | — | $443.0M | $210.0M | $220.0M |
| SG&A Expense | $1.72B | $1.76B | $1.89B | $1.70B | $1.67B | $1.36B | $1.44B |
| Operating Income | $929.0M | $1.33B | $1.20B | $1.54B | $1.79B | $2.75B | $3.70B |
| Operating Margin | 14.9% | 20.7% | 19.2% | 25.0% | 28.3% | 42.1% | 47.5% |
| Interest Expense | $504.0M | $520.0M | $527.0M | $422.0M | $258.0M | $0 | $0 |
| Pretax Income | $425.0M | $807.0M | $673.0M | $1.12B | $1.53B | $2.75B | $3.70B |
| Income Tax Expense | $238.0M | $-57.0M | $-350.0M | $205.0M | $178.0M | $496.0M | $390.0M |
| Net Income | $187.0M | $864.0M | $1.02B | $917.0M | $1.35B | $2.16B | $3.22B |
| Net Margin | 3.0% | 13.5% | 16.3% | 14.9% | 21.4% | 33.1% | 41.4% |
| EPS (Basic) | $0.72 | $3.36 | $4.01 | $3.61 | $5.33 | $8.52 | $12.69 |
| EPS (Diluted) | $0.72 | $3.33 | $3.99 | $3.59 | $5.31 | $8.52 | $12.69 |
| Shares Outstanding (Basic) | 259.5M | 257.0M | 255.2M | 254.1M | 253.5M | 253.5M | 253.5M |
| Shares Outstanding (Diluted) | 260.8M | 259.2M | 256.3M | 255.2M | 254.2M | 253.5M | 253.5M |
| Dividends Per Share | $0.34 | $1.12 | $1.12 | $1.12 | $0.56 | — | — |